{
    "info": {
        "nct_id": "NCT05398302",
        "official_title": "Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy",
        "inclusion_criteria": "* Volunteer patient\n* Histologically confirmed prostate cancer\n* Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial\n* Based on positron emission tomography (PET)/computed tomography (CT) images: Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy\n* Platelets > 75,000/ul within 14 days prior to biopsy\n* Prothrombin time (PT) or International normalized ratio (INR) and a partial thromboplastin time (PTT) < 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy\n* Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for one week prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is agreement regarding the procedure between the treating physician, the interventional radiologist and the principal investigator (PI)\nHealthy volunteers allowed\nMust be MALE",
        "exclusion_criteria": "* Patients with significant congenital or acquired bleeding disorders (e.g. von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histologically confirmed prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed prostate cancer",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets > 75,000/ul within 14 days prior to biopsy",
            "criterions": [
                {
                    "exact_snippets": "Platelets > 75,000/ul",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 75000,
                                "unit": "/ul"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days prior to biopsy",
                    "criterion": "platelet count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time window before biopsy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Based on positron emission tomography (PET)/computed tomography (CT) images: Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy",
            "criterions": [
                {
                    "exact_snippets": "Evidence of lymph node or soft tissue metastatic disease",
                    "criterion": "lymph node or soft tissue metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "amenable to image-guided biopsy",
                    "criterion": "metastatic disease amenability to image-guided biopsy",
                    "requirements": [
                        {
                            "requirement_type": "amenability to image-guided biopsy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Volunteer patient",
            "criterions": [
                {
                    "exact_snippets": "Volunteer patient",
                    "criterion": "volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "volunteer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prothrombin time (PT) or International normalized ratio (INR) and a partial thromboplastin time (PTT) < 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin time (PT) ... < 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days prior to biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "International normalized ratio (INR) ... < 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days prior to biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) < 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days prior to biopsy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for one week prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is agreement regarding the procedure between the treating physician, the interventional radiologist and the principal investigator (PI)",
            "criterions": [
                {
                    "exact_snippets": "Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for one week prior to the biopsy",
                    "criterion": "anti-coagulation therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to tolerate discontinuation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "discontinuation duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is agreement regarding the procedure between the treating physician, the interventional radiologist and the principal investigator (PI)",
                    "criterion": "conversion to low molecular weight heparin",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agreement between",
                            "expected_value": [
                                "treating physician",
                                "interventional radiologist",
                                "principal investigator"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial",
            "criterions": [
                {
                    "exact_snippets": "Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial",
                    "criterion": "eligibility for 177Lu-PSMA-617",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "access pathway",
                            "expected_value": [
                                "expanded access protocol (IRB# 21-5010)",
                                "approved trial"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with significant congenital or acquired bleeding disorders (e.g. von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible",
            "criterions": [
                {
                    "exact_snippets": "significant congenital or acquired bleeding disorders (e.g. von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible",
                    "criterion": "bleeding disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "congenital",
                                "acquired"
                            ]
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}